Rapid Molecular Flu Testing Platforms Market Report 2026

Rapid Molecular Flu Testing Platforms Market Overview

• Rapid Molecular Flu Testing Platforms market size has reached to $2.71 billion in 2025 • Expected to grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: Surge In Seasonal And Pandemic Influenza Outbreaks Fueling The Growth Of The Market Due To High Population Mobility And Rapid Virus Transmission • Market Trend: High-Throughput Detection of Respiratory Viruses Enabled by cobas Respiratory flex Test • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rapid Molecular Flu Testing Platforms Market?

Rapid molecular flu testing platforms are advanced diagnostic systems designed to quickly detect influenza viruses using molecular techniques such as pcr or isothermal amplification. These platforms provide accurate results within a short time, enabling timely identification of viral infections. They leverage sensitive and specific technology to detect viral genetic material, improving the reliability and speed of influenza testing. The main product types of rapid molecular flu testing platforms include benchtop platforms, portable platforms, and other product types. Benchtop platforms refer to compact laboratory systems designed to perform rapid molecular testing for influenza detection. The sample types include nasopharyngeal swabs, throat swabs, saliva, and other sample types with different technologies that include reverse transcription polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification, clustered regularly interspaced short palindromic repeats (CRISPR) based, and other technologies. The distribution channels include direct sales, distributors, online sales, and other distribution channels, and they are used by several end users such as hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

What Is The Rapid Molecular Flu Testing Platforms Market Growth Forecast?

The rapid molecular flu testing platforms market size is expected to see rapid growth in the next few years. It will grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to integration with ai and iot for rapid diagnostics, expansion of portable and point-of-care platforms, development of multiplex and high-throughput testing systems, rising investment in molecular diagnostic technologies, growth of home-based and decentralized testing. Major trends in the forecast period include rapid point-of-care testing expansion, multiplex molecular diagnostics, integration with laboratory information systems, automated sample processing, high-throughput testing platforms.

Global Rapid Molecular Flu Testing Platforms Market Segmentation

1) By Product Type: Benchtop Platforms, Portable Platforms, Other Product Types 2) By Sample Type: Nasopharyngeal Swabs, Throat Swabs, Saliva, Other Sample Types 3) By Technology: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based, Other Technologies 4) By Distribution Channel: Direct Sales, Distributors, Online Sales, Other Distribution Channels 5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users Subsegments: 1) By Benchtop Platforms: Multiplex Testing Platform, High Throughput Platform, Automated Sample Processing Platform, Standard Laboratory Platform 2) By Portable Platforms: Handheld Testing Platform, Point Of Care Testing Platform, Battery Operated Portable Platform, Field Deployable Platform 3) By Other Product Types: Integrated Workflow Platform, Compact Diagnostic Platform, Rapid Screening Platform, Custom Configured Platform

What Is The Driver Of The Rapid Molecular Flu Testing Platforms Market?

The increasing incidence of seasonal and pandemic influenza outbreaks is expected to propel the growth of the rapid molecular flu testing platforms market. Seasonal and pandemic influenza outbreaks refer to the recurring or widespread occurrence of influenza infections caused by circulating or novel influenza viruses. The rising frequency and intensity of these outbreaks are driven by factors such as high population mobility, frequent international travel, urban crowding, viral mutation, and suboptimal vaccination coverage, all of which facilitate rapid virus transmission. Rapid molecular flu testing platforms play a critical role in managing seasonal and pandemic influenza outbreaks by enabling fast and highly accurate detection of influenza viruses, supporting timely clinical decision-making, early treatment initiation, and effective infection control measures. For instance, in February 2026, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, for the 2025–2026 influenza season, influenza infections in the United States resulted in approximately 290,000–450,000 hospitalizations and 34,000–53,000 deaths, underscoring the substantial public health and economic burden of the disease. Therefore, increasing global incidence of seasonal and pandemic influenza outbreaks is driving the growth of the rapid molecular flu testing platforms industry.

Key Players In The Global Rapid Molecular Flu Testing Platforms Market

Major companies operating in the rapid molecular flu testing platforms market are Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers, Becton Dickinson (BD), bioMérieux, Bio-Rad Laboratories, Qiagen N.V., Seegene Inc., BioPerfectus, Fapon Biotech, Visby Medical, Vircell S.L., QuantuMDx Group, Altona Diagnostics, Creative Diagnostics, Princeton BioMeditech Corporation, Credo Diagnostics, Genetic Signatures Ltd, AccuBioTech, Kogene Co. Ltd., Ameritek Inc., Alpha Diagnostic Intl, Medlere Ltd, ProtonDx Ltd.

Global Rapid Molecular Flu Testing Platforms Market Trends and Insights

Major companies operating in the rapid molecular flu testing platforms market are increasingly focusing on the development of advanced multiplex molecular solutions, such as temperature-activated generation of signal (TAGS) technology, to enable high-throughput and simultaneous detection of multiple respiratory pathogens, including influenza A and B, from a single patient sample. TAGS technology is an advanced PCR innovation that allows differentiation of multiple genetic targets within a single fluorescence channel, enabling up to 15 diagnostic results in one test well. For instance, in September 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company launched the cobas Respiratory flex test. The test enables rapid detection of up to 12 respiratory viruses, including influenza A and B, when run on Roche’s cobas 5800, 6800, and 8800 high-throughput molecular systems. This solution supports flexible, syndromic panel testing with high throughput, optimizing laboratory workflows and resources while facilitating accurate and timely diagnosis of respiratory infections.

What Are Latest Mergers And Acquisitions In The Rapid Molecular Flu Testing Platforms Market?

In April 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Lucira Health, Inc. for an undisclosed amount. With this acquisition, Pfizer aimed to expand its presence in the rapid molecular flu testing platforms market by integrating Lucira’s at-home nucleic acid amplification technology for the rapid detection of influenza A and B and other respiratory infections, strengthening its diagnostics portfolio and enhancing its capability to deliver convenient, point-of-care and over-the-counter molecular testing solutions. Lucira Health, Inc. is a US-based molecular diagnostics company specializing in rapid at-home infectious disease testing platforms, including molecular influenza detection tests.

Regional Insights

North America was the largest region in the rapid molecular flu testing platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rapid Molecular Flu Testing Platforms Market?

The rapid molecular flu testing platforms market consists of revenues earned by entities by providing services such as technical support, training and education, quality control services, and maintenance and calibration. The market value includes the value of related goods sold by the service provider or included within the service offering. The rapid molecular flu testing platforms market includes sales of isothermal amplification devices, disposable test cartridges, sample collection swabs, and assay reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Rapid Molecular Flu Testing Platforms Market Report 2026?

The rapid molecular flu testing platforms market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rapid molecular flu testing platforms industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.